SCHEMBL24348037

SCHEMBL24348037

Cc1nc(CNC(=O)C(C)(C)C)sc1-c1csc(-c2cc(F)c(O)c(F)c2F)n1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 4/20 0.60
▸ PI4KB Q9UBF8 7/20 0.39
▸ CFTR P13569 4/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ LMNA P02545 4/20 0.35
▸ MAPT P10636 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ ALB P02768 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ HTT P42858 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NR2F2 P24468 1/20 0.34
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24348501 0.89 BPGM (0.63) BPGMPI4KBMEN1LMNAMAPT
SCHEMBL24348954 0.89 BPGM (0.53) BPGMPI4KBCFTRMEN1LMNA
SCHEMBL24348036 0.88 BPGM (0.61) BPGMPI4KBMEN1LMNAMAPT
SCHEMBL24348548 0.88 BPGM (0.77) BPGMPI4KBMEN1LMNAMAPT
SCHEMBL24271860 0.83 BPGM (0.51) BPGMPI4KBCFTRMEN1LMNA
SCHEMBL24348498 0.82 BPGM (0.57) BPGMPI4KBPIK3CGPIK3CDPIK3CA
SCHEMBL24348035 0.82 BPGM (0.55) BPGMMEN1KMT2APIK3CGPIK3CD
SCHEMBL24349250 0.82 BPGM (0.55) BPGMMEN1MAPTKMT2AKDM4E
SCHEMBL24348039 0.82 BPGM (0.71) BPGMPI4KBMEN1LMNAMAPT
SCHEMBL24348059 0.81 BPGM (0.41) BPGMPI4KBCFTRPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885PI4KB 781/4885CFTR 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback